Read by QxMD icon Read

colorectal cancer and early detection

Fernando Velayos, Priya Kathpalia, Emily Finlayson
This review chronicles the evolution of dysplasia detection and management in IBD since 1925, the year the first case report of colitis-related colorectal cancer was published. We have grouped advances in colorectal cancer research, endoscopic techniques, surgery, and technology into 4 unequally timed eras, before colonoscopy, early era of colonoscopy, new century, and 2017 and beyond. We conclude that colorectal cancer prevention and dysplasia management for patients with IBD has changed over these periods, from somewhat hopeless to hopeful...
October 17, 2016: Gastroenterology
Chao Fang, Chuanwen Fan, Cun Wang, Qiaorong Huang, Wentong Meng, Yongyang Yu, Lie Yang, Zhihai Peng, Jiankun Hu, Yuan Li, Xianming Mo, Zongguang Zhou
INTRODUCTION: Liver is the most common site of distant metastasis in colorectal cancer (CRC). Early diagnosis and appropriate treatment selection decides overall prognosis of patients. However, current diagnostic measures were basically imaging but not functional. Circulating tumor cells (CTCs) known as hold the key to understand the biology of metastatic mechanism provide a novel and auxiliary diagnostic strategy for CRC with liver metastasis (CRC-LM). RESULTS: The expression of CD133+ and CD133+CD54+CD44+ cellular subpopulations were higher in the peripheral blood of CRC-LM patients when compared with those without metastasis (P<0...
October 15, 2016: Oncotarget
Qiang Li, Keke Wang, Chang Su, Jieyu Fang
Colorectal cancer is one of the most frequent causes of cancer-related deaths worldwide. Thus, there is a need for timely diagnosis and effective treatment. Our aim in the present study was to detect the serum level of trefoil factor 3 protein and evaluate the diagnostic accuracy of trefoil factor 3 in patients with colorectal cancer. We collected serum samples from 204 participants (127 patients with colorectal cancer, 35 patients with polyps, and 42 healthy controls). The levels of serum trefoil factor 3 and carcinoembryonic antigen expression were measured by enzyme-linked immunosorbent assay...
October 19, 2016: Technology in Cancer Research & Treatment
Sohei Kobayashi, Tyuji Hoshino, Takaki Hiwasa, Mamoru Satoh, Bahityar Rahmutulla, Sachio Tsuchida, Yuji Komukai, Tomoaki Tanaka, Hisahiro Matsubara, Hideaki Shimada, Fumio Nomura, Kazuyuki Matsushita
Anti-PUF60, poly(U)-binding-splicing factor, autoantibodies are reported to be detected in the sera of dermatomyositis and Sjogren's syndrome that occasionally associated with malignancies. PUF60 is identical with far-upstream element-binding protein-interacting repressor (FIR) that is a transcriptional repressor of c-myc gene. In colorectal cancers, a splicing variant of FIR that lacks exon2 (FIRΔexon2) is overexpressed as a dominant negative form of FIR. In this study, to reveal the presence and the significance of anti-FIRs (FIR/FIRΔexon2) antibodies in cancers were explored in the sera of colorectal and other cancer patients...
October 15, 2016: Oncotarget
Joannie Lortet-Tieulent, Isabelle Soerjomataram, Chun Chieh Lin, Jan Willem W Coebergh, Ahmedin Jemal
INTRODUCTION: In the U.S., people of different races/ethnicities have differences in cancer incidence, mortality, survival, stage at diagnosis, and receipt of treatment, resulting in variances in cancer burden. The burden of cancer in 2011 was assessed by race/ethnicity for 24 cancers using disability-adjusted life years (DALYs). METHODS: In 2014-2015, DALYs and their two components were estimated (years of life lost [YLLs] and years lived with disability) by race/ethnicity using population-based cancer registry data collected in 2013, vital statistics, and literature reviews...
November 2016: American Journal of Preventive Medicine
Khurum Khan, Avani Athauda, Katharine Aitken, David Cunningham, David Watkins, Naureen Starling, Gary J Cook, Eleftheria Kalaitzaki, Ian Chau, Sheela Rao
BACKGROUND: This study had two aims: (a) to evaluate the utility of fluorine 18-fluorodeoxyglucose (FDG) positron emission tomography (PET)-computed tomography (CT) in detecting occult disease recurrence with raised carcinoembryonic antigen (CEA) and (b) to establish the prognostic effects of early detection of disease recurrence in patients with colorectal cancer (CRC). PATIENTS AND METHODS: Clinico-pathological data were obtained from all consecutive patients undergoing CRC surveillance from 2004 to 2010 who had an elevated CEA level (>3 ng/mL in nonsmokers, >5 ng/mL in smokers) but normal or equivocal conventional investigations...
October 14, 2016: Oncologist
Michael David Williams, Lingling Xian, Tait Huso, Jeong-Jin Park, David Huso, Leslie M Cope, David R Gang, William F Siems, Linda Resar, Raymond Reeves, Herbert H Hill
Because colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, more accessible screening tests are urgently needed to identify early-stage lesions. We hypothesized that highly sensitive, metabolic profile analysis of stool samples will identify metabolites associated with early-stage lesions and could serve as a noninvasive screening test. We therefore applied travelling wave ion mobility mass spectrometry (TWIMMS) coupled with ultra-performance liquid chromatography (UPLC) to investigate metabolic aberrations in stool samples in a transgenic model of pre-malignant polyposis aberrantly expressing the gene encoding the high mobility group A (Hmga1) chromatin remodeling protein...
October 4, 2016: Journal of Proteome Research
Emily B Peterson, Jamie S Ostroff, Katherine N DuHamel, Thomas A D'Agostino, Marisol Hernandez, Mollie R Canzona, Carma L Bylund
Cancer screening is critical for early detection and a lack of screening is associated with late-stage diagnosis and lower survival rates. The goal of this review was to analyze studies that focused on the role of provider-patient communication in screening behavior for cervical, breast, and colorectal cancer. A comprehensive search was conducted in four online databases between 1992 and 2016. Studies were included when the provider being studied was a primary care provider and the communication was face-to-face...
September 28, 2016: Preventive Medicine
Kyungjin Lee, Lynnette R Ferguson
Colorectal cancer is a major global cause of morbidity and mortality. Current strategies employed to increase detection of early, curable stages of this disease are contributing to a reduction of the negative health impact from it. While there is a genetic component to the risk of disease, diet and environment are known to have major effects on the risk of an individual for developing the disease. However, there is the potential to reduce the impact of this disease further by preventing disease development...
September 7, 2016: World Journal of Gastroenterology: WJG
Huanyu Ju, Wenjing Xing, Jinfeng Yang, Yang Zheng, Xiuzhi Jia, Benning Zhang, Huan Ren
BACKGROUND: Despite recent advances in early detection and improvements in chemotherapy for colon cancer, the patients still face poor prognosis of postoperative recurrence and metastasis, the median survival for patients with metastatic colorectal cancer is approximately 22-24 months. Some immunotherapeutic approaches had been attempted in colon cancer patients to significantly increase overall survival. A vaccine based approach has shown a novel direction for colon cancer prevention and therapy...
September 26, 2016: BMC Immunology
Manveen K Sethi, William S Hancock, Susan Fanayan
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide. Delineating biological markers (biomarkers) for early detection, when treatment is most effective, is key to prevention and long-term survival of patients. Development of reliable biomarkers requires an increased understanding of the CRC biology and the underlying molecular and cellular mechanisms of the disease. With recent advances in new technologies and approaches, tremendous efforts have been put in proteomics and genomics fields to deliver detailed analysis of the two major biomolecules, genes and proteins, to gain a more complete understanding of cellular systems at both genomic and proteomic levels, allowing a mechanistic understanding of the human diseases, including cancer, and opening avenues for identification of novel gene and protein based prognostic and therapeutic markers...
October 18, 2016: Accounts of Chemical Research
Kazuhiko Uchiyama, Nobuaki Yagi, Katsura Mizushima, Yasuki Higashimura, Yasuko Hirai, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Katada, Kazuhiro Kamada, Osamu Handa, Takeshi Ishikawa, Tomohisa Takagi, Hideyuki Konishi, Yoshiaki Kuriu, Masayoshi Nakanishi, Eigo Otsuji, Yoshito Itoh, Yuji Naito
BACKGROUND: Although colorectal cancer (CRC) is one of the most common causes of cancer mortality, early-stage detection improves survival rates dramatically. Because cancer impacts important metabolic pathways, the alteration of metabolite levels as a potential biomarker of early-stage cancer has been the focus of many studies. Here, we used CE-TOFMS, a novel and promising method with small injection volume and high resolution, to separate and detect ionic compounds based on the different migration rates of charged metabolites in order to detect metabolic biomarkers in patients with CRC...
September 20, 2016: Journal of Gastroenterology
Charlotte Vrinten, Lesley M McGregor, Małgorzata Heinrich, Christian von Wagner, Jo Waller, Jane Wardle, Georgia B Black
BACKGROUND: Cancer has long inspired fear, but the effect of fear is not well understood; it seems both to facilitate and to deter early diagnosis behaviours. To elucidate fear's behavioural effects, we systematically reviewed and synthesised qualitative literature to explore what people fear about cancer. METHODS: We searched Medline, Embase, PsycInfo, Web of Science, AnthroSource, and Anthrobase for studies on cancer fear in breast, cervical, and colorectal cancer screening and analysed 102 studies from 26 countries using thematic synthesis...
September 19, 2016: Psycho-oncology
N V Soldatkina, O I Kit, Yu A Gevorkyan, A G Milakin
AIM: to define some clinical characteristics of synchronous and metachronous colorectal cancer (CRC). MATERIAL AND METHODS: The investigation was concerned with the data of 150 patients with T1-4N0-2M0-1 multiple primary CRC. The clinical, biological, and morphological characteristics of synchronous and metachronous tumors were analyzed. RESULTS: Multiple primary tumors were 6.01% of all the cases of CRC. There was a preponderance of synchronous CRC (63...
2016: Terapevticheskiĭ Arkhiv
John Bian
As a standard way for prevention and early detection of colorectal cancer (CRC), colonoscopy has been used for CRC screening in the United States for more than one decade. An article entitled "Assessing Colorectal Cancer Screening Adherence of Medicare Fee-For-Service Beneficiaries Age 76 to 95 Years" recently published at the Journal of Oncology Practice reports the trends in overuse of CRC screening services among average-risk elderly populations at the age of 76-95 years. Several reasons for overusing colonoscopy have been postulated, and some strategies for reducing overuse of CRC screening services have also been proposed...
2016: Chinese Journal of Cancer
Hadi Babaei, Mohsen Mohammadi, Rasoul Salehi
BACKGROUND: The early detection of colorectal cancer (CRC) with high sensitivity screening is essential for the reduction of cancer-specific mortality. Abnormally methylated genes that are responsible for the pathogenesis of cancers can be used as biomarkers for the detection of CRC. The methylation status of the secreted frizzled-related protein 2 (SFRP2) gene was evaluated for their use as a marker in the noninvasive detection of CRC. MATERIALS AND METHODS: Methylation-specific polymerase chain reaction was performed to analyze the promoter CpG methylation of SFRP2 in the fecal DNA of 25 patients with CRC and 25 individuals exhibiting normal colonoscopy results...
July 2016: Nigerian Medical Journal: Journal of the Nigeria Medical Association
Louise Rasmussen, Michael Wilhelmsen, Ib Jarle Christensen, Jens Andersen, Lars Nannestad Jørgensen, Morten Rasmussen, Jakob W Hendel, Mogens R Madsen, Jesper Vilandt, Thore Hillig, Michael Klærke, Anna-Marie Bloch Münster, Lars M Andersen, Berit Andersen, Nete Hornung, Erland J Erlandsen, Ali Khalid, Hans Jørgen Nielsen
BACKGROUND: Programs for population screening of colorectal cancer (CRC) have been implemented in several countries with fecal immunochemical testing (FIT) as the preferred platform. However, the major obstacle for a feces-based testing method is the limited compliance that reduces the clinical sensitivity for detection of participants with non-symptomatic CRC. Therefore, research approaches have been initiated to develop screening concepts based on biomarkers in blood. Preliminary results show that protein, genetic, epigenetic, and metabolomic components may be valuable in blood-based screening concepts, particularly when combinations of the various components appear to lead to significant improvements...
2016: JMIR Research Protocols
Laura Huth, Jörg Jäkel, Edgar Dahl
Colorectal cancer, a clinically diverse disease, is a leading cause of cancer-related death worldwide. Application of novel molecular diagnostic tests, which are summarized in this article, may lead to an improved survival of colorectal cancer patients.  Distinction of these applications is based on the different molecular principles found in colorectal cancer (CRC). Strategies for molecular analysis of single genes (as KRAS or TP53) as well as microarray based techniques are discussed. Moreover, in addition to the fecal occult blood testing (FOBT) and colonoscopy some novel assays offer approaches for early detection of colorectal cancer like the multitarget stool DNA test or the blood-based Septin 9 DNA methylation test...
2014: Microarrays
Zhonglin Liu, Brian D Gray, Christy Barber, Michael Bernas, Minying Cai, Lars R Furenlid, Andrew Rouse, Charmi Patel, Bhaskar Banerjee, Rongguang Liang, Arthur F Gmitro, Marlys H Witte, Koon Y Pak, James M Woolfenden
Molecular probes capable of detecting colorectal cancer (CRC) are needed for early CRC diagnosis. The objective of this study was to characterize c[CTPSPFSHC]OH (TCP-1), a small peptide derived from phage display selection, for targeting human CRC xenografts using technetium-99m ((99m)Tc)-labeled TCP-1 and fluorescent cyanine-7 (Cy7)-labeled form of the peptide (Cy7-TCP-1). (99m)Tc-TCP-1 was generated by modifying TCP-1 with succinimidyl-6-hydrazino-nicotinamide (S-HYNIC) followed by radiolabeling. In vitro saturation binding experiments were performed for (99m)Tc-TCP-1 in human HCT116 colon cancer cells...
October 10, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
H M C Shantha Kumara, David Gaita, Hiromichi Miyagaki, Xiaohong Yan, Sonali Ac Hearth, Linda Njoh, Vesna Cekic, Richard L Whelan
AIM: To assess blood chitinase 3-like 1 (CHi3L1) levels for 2 mo after minimally invasive colorectal resection (MICR) for colorectal cancer (CRC). METHODS: CRC patients in an Institutional Review Board approved data/plasma bank who underwent elective MICR for whom preoperative (PreOp), early postoperative (PostOp), and 1 or more late PostOp samples [postoperative day (POD) 7-27] available were included. Plasma CHi3L1 levels (ng/mL) were determined in duplicate by enzyme linked immunosorbent assay...
August 15, 2016: World Journal of Gastrointestinal Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"